Troponin T (HS), Blood

Lab area

Clinical Biochemistry - General

Method and equipment

Equipment : Roche Cobas Pro e801

Method : Sandwich principle. Total duration of assay: 18 minutes.
▪ 1st incubation: Antigen in the sample (30 µL), a biotinylated monoclonal cardiac troponin T‑specific antibody, and a monoclonal cardiac troponin T‑specific antibody labeled with a ruthenium complexa) react to form a sandwich complex.
▪ 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
Total duration of assay: 9 minutes.
▪ During a 9‑minute incubation, antigen in the sample (30 μL), a biotinylated monoclonal cardiac troponin T‑specific antibody, a monoclonal cardiac troponin T‑specific antibody labeled with a ruthenium complex and streptavidin-coated microparticles react to form a sandwich complex, which is bound to the solid phase.
For both assay applications:
▪ The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
▪ Results are determined via a calibration curve which is instrument specifically generated by 2‑point calibration and a master curve provided via the cobas link.

Expected turn-around time

STAT: 1 hour Urgent: 3 Hours Routine: 24 Hours

Background and clinical significance

Immunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma. This assay can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction (AMI), and as an aid for early discharge and outpatient management for patients suspected of acute coronary syndrome (ACS). The test is further indicated for the risk stratification of patients presenting with acute coronary syndrome and for cardiac risk in patients with chronic renal failure. The test may also be useful for the selection of more intensive therapy and intervention in patients with elevated levels of cardiac troponin T (cTnT).
In addition, this test can be used in the context of non‑cardiac surgeries to predict pre‑operatively the perioperative risk of major adverse cardiac events and in diagnosis of perioperative myocardial infarction (PMI) and myocardial injuries after non-cardiac surgeries (MINS). The cTnT‑hs values may also be used, in conjunction with clinical and diagnostics findings, to aid in stratifying the long-term risk of cardiovascular death, myocardial infarction, coronary revascularization, heart failure or ischemic stroke, and all-cause mortality in asymptomatic individuals.